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Re: Radiation Therapy in the
Treatment of Hodgkin’s
Disease—Do You See What I
See?
Learn what is true in order to do what
is right.
Thomas H. Huxley (1825–1895)
In his recent editorial (1) regarding
our paper (2), Longo suggests that there
is no foundation for radiation therapy in
combination with chemotherapy for pa-
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tients with Hodgkin’s lymphoma. We
agree that one should always aim at min-
imal treatment intensity; however, this
should not endanger individual patients’
cure rates.
Hence, the challenge is to properly
select patients requiring radiation ther-
apy. The rationale for radiation therapy
is the observation that relapses usually
involve initially involved sites and that
radiation therapy reduces recurrence
rates (3). In a randomized trial carried
out by the European Organization for
Research and Treatment of Cancer
(EORTC) Lymphoma Group, radiation
therapy did not improve outcomes in the
57% of advanced Hodgkin’s lymphoma
patients who were in complete remission
after chemotherapy with six to eight cy-
cles of mechlorethamine, vincristine,
procarbazine, prednisone–doxorubicin,
bleomycin, and vinblastin (MOPP–ABV
hybrid) (4). However, the 34% of pa-
tients who were in partial remission af-
ter chemotherapy and then received field
radiation experienced cure rates as high
as those experienced by patients in com-
plete remission after chemotherapy. Ra-
diation therapy also appears to be
needed for patients with early-stage dis-
ease with favorable characteristics who
are treated with mild chemotherapy. In-
deed, the EORTC Lymphoma Group
had to close the arm of an ongoing trial,
H9F, in which patients did not receive
radiation therapy after achieving a com-
plete remission with epirubicin, bleomy-
cin, vinblastin, and prednisone (EBVP)
chemotherapy because of the high num-
ber of relapses in that arm (Noordijk EM,
Thomas J: personal communication).
Longo’s suggestion that 80%–85%
of Hodgkin’s lymphoma patients can be
cured without radiation therapy is not
supported by present evidence for pa-
tients with early or advanced Hodgkin’s
disease. For example, Duggan et al. (5)
reported 5-year failure-free survival
rates of only 63% (95% confidence in-
terval [CI]  59% to 68%) for patients
with advanced Hodgkin’s disease. De-
spite successful salvage treatment in a
substantial number of patients, the
5-year overall survival was only 82%
(95% CI  79% to 86%). Importantly,
salvage treatment has been shown to be
related to excess late morbidity and
mortality (6,7).
Longo also worries about the inter-
pretation of the risk of breast cancer
after a relatively low dose of radiation.
Our conclusion, that the risk of breast
cancer increases with increasing radia-
tion dose up to at least 40 Gy, has the
important implication that the lower ra-
diation doses used presently (20–30 Gy
in fractions of 2 Gy) may reduce the
increased breast cancer risk compared
with the radiation schedules used in the
past (equivalent to 40 Gy in fractions of
2 Gy). The relative risk of developing
breast cancer was not statistically signif-
icantly increased in patients who re-
ceived doses of 4–23.2 Gy (median 15
Gy) to the area of the breast where the
tumor developed as compared with pa-
tients who received less than 4 Gy, but
we made no suggestions as to “safe”
levels of radiation. Indeed, we cautioned
readers about the elevated risks of late
morbidity after treatment with new mo-
dalities (2).
Finally, Longo notes that the ABVD
(doxorubicin, bleomycin, vinblastin,
dacarbazine) regimen has replaced most
alkylating agent–based regimens, and
he notes that it has low toxicity. How-
ever, doxorubicin-associated cardiovas-
cular damage and bleomycin-induced
pulmonary toxicity are important side
effects. Moreover, fatal toxicity has
been reported in 2%–3% of patients
treated with ABVD alone (5).
In conclusion, it is important to re-
strict the intensity of treatment for
young patients with Hodgkin’s lym-
phoma to the greatest extent possible.
ABVD is an effective regimen, but un-
fortunately it cannot, as sole treatment
modality, cure 80%–85% of patients.
Our primary concern is to cure patients
of their Hodgkin’s lymphoma. Unfortu-
nately, new trials have to be designed
before long-term toxicity results of the
previous trials are available. Balancing
the risks of primary or secondary treat-
ment failure against the risk of late mor-
bidity is extremely difficult and should
be done on the basis of the results of
both retrospective and prospective studies.
BERTHE M. P. ALEMAN
NICOLA S. RUSSELL
HARRY BARTELINK
FLORA E. VAN LEEUWEN
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RESPONSE
Near the end of “Butch Cassidy and
the Sundance Kid,” the heroes, sur-
rounded by the Bolivian cavalry, are
about to charge out to meet their fate
when Butch asks Sundance, “You didn’t
see Lefors out there, did you?” Joe Le-
fors was the leader of the highly skilled
posse that had tracked the two across
much of North America. “Lefors? No,”
answers Sundance. “Good. For a mo-
ment there, I thought we were in trou-
ble.” Butch and Sundance did not accu-
rately assess their risks, overestimating a
small risk and underestimating a huge
one.
Aleman et al. make two major points.
First, radiation therapy may help people
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who do not achieve a complete response
with chemotherapy alone. I agree. The
first study to show this benefit was
Southwest Oncology Group (SWOG)
Study 7808 (1). Second, ABVD (doxo-
rubicin, bleomycin, vinblastine, dacar-
bazine) cannot cure 85% of patients
with Hodgkin’s disease. If ABVD alone
were as good as MOPP (mechloreth-
amine, vincristine, procarbazine, pred-
nisone) alone, it would achieve a 92%
10-year survival in early-stage disease
(2). The study cited by the authors re-
ports a 5-year survival of 82% in
advanced-stage Hodgkin’s disease. If
chemotherapy cannot cure 80%–85% of
all patients with Hodgkin’s disease, it
comes close.
According to Surveillance, Epidemi-
ology, and End Results (SEER)1 Pro-
gram data (3), 5-year survival from
Hodgkin’s disease for the period 1992
through 1998 was 84%. Despite this
high level of successful treatment and
the very long period of time that the
most successful treatment tools have
been available (radiation therapy since
the 1960s, MOPP since 1970, ABVD
since 1975), a paucity of long-term
follow-up data exist to assess the impact
of treatment on cured patients.
So far, perhaps because radiation
therapists have done a better job of
studying the impact of their treatment,
the late effects of radiation therapy ap-
pear to be alarmingly serious and fre-
quent. Ng et al. (4) showed that more of
their patients treated for Hodgkin’s dis-
ease with radiation therapy have died
from effects of the treatment (101
deaths) than have died from Hodgkin’s
disease (60 deaths). They project about
10% of patients dying from second can-
cers and 3% from heart disease at 20
years after treatment, based on a median
follow-up of only 12 years. Other stud-
ies have documented a second cancer
risk of about 1% per year extending at
least 25 years after treatment and possi-
bly beyond.
Comparable data from patients
treated with chemotherapy alone are
even more sparse. Long-term follow-up
of MOPP-treated patients does not
suggest any late death or toxicity when
chemotherapy alone is used. Patients
receiving therapy with MOPP plus ra-
diation have a 3% lifetime risk of
acute leukemia, and all the risk occurs
in the first decade after treatment (5).
In patients who survive beyond 10
years after treatment, the risk of leu-
kemia appears to be no greater than in
people who never had Hodgkin’s dis-
ease. Other life-threatening late toxic-
ities are anecdotal or unsupported by
data from large groups of patients.
Data on ABVD-treated patients are
virtually nonexistent other than occa-
sional anecdotes. Acute toxicity ap-
pears lower with ABVD than with
MOPP (the Cancer and Leukemia
Group B [CALGB] mortality data
quoted by Aleman et al. are several
times higher than those reported from
other centers). Of course, absence of
evidence is not evidence of absence but,
given more than 28 years of use, it
would be surprising if a life-threatening
late toxicity from ABVD affecting as
many as 10% of the patients would have
been missed.
No one contests the attribution of late
toxicity to radiation therapy. However,
the magnitude of the risk has not been
widely appreciated. I doubt that any re-
search protocol using radiation therapy
actually informs the patients that their
risk of dying from a radiation therapy–
related complication exceeds their risk
of dying from Hodgkin’s disease. In-
stead, the approach has been to hope that
lowering the dose of radiation therapy
and/or limiting the field size will reduce
the enormous late risks of second cancer
and heart disease. This approach is not
currently supported by data. Upton (6)
demonstrated more than 40 years ago
that the risk of cancer in animals receiv-
ing radiation follows a bell-shaped
dose–response curve. Thus, lowering ra-
diation doses might actually increase the
risk of a second cancer. In the absence
of data, one cannot assume that lower
doses of radiation therapy are safer.
We sorely need additional data on
long-term effects of treatment in pa-
tients with Hodgkin’s disease. In the in-
terim, on the basis of current informa-
tion, the safest approach to managing
these patients is to avoid the routine use
of radiation therapy in all patients. Cure
as many patients as you can with che-
motherapy alone, reserving radiation
therapy for two subgroups: those who
fail to obtain a complete response to
chemotherapy, and those with very large
mediastinal masses. Patients who re-
lapse should be rescued with high-
dose chemotherapy (without radiation
therapy, if possible) and autologous
hematopoietic stem cells. This ap-
proach needs to be compared in large-
scale studies with combined modality
treatment approaches for response
rate, relapse rate, complications, and
survival. To continue with a treatment
approach that exposes every patient to
the risks of radiation therapy is to re-
peat the error in judgment of Butch
and Sundance: underestimating a huge
risk and overestimating a small one.
DAN L. LONGO
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